Home › Compare › MHPSY vs ABBV
MHPSY yields 25.01% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 3
Combined, MHPSY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MHPSY + ABBV for your $10,000?
MHP SE, together with its subsidiaries, produces and sells food and poultry products in Ukraine and internationally. It operates in four segments: Poultry & Related Operations, Grain Growing Operations, Meat-Processing & Other Agricultural Operations, and European Operating. The Poultry & Related Operations segment produces and sells fresh and frozen chicken meats, vegetable oils, including sunflower and soybean, as well as mixed fodder under the brand Nasha Riaba, Apetytna, Baschinsky, Vinnytski Kurchata, Kurator, Sultanah, Assilah, Al-Hassanat, Home Style Chicken, Ukrainian Chicken, and Chef's Secrets names to export markets. The company's Grain Growing Operations segment grows crops for fodder production and sale to third parties. Its Meat-Processing & Other Agricultural Operations segment produces and sells sausages, processed and cooked meats, convenience foods, and produce from cattle and diary operations under the Bashchinsky, Lehko!,Qualiko, Skott Smeat, and Sytni brands. The European Operating segment engages in the production and sale of chicken meat and processed poultry meat products under the PP and Poli brands. It is also involved in hatching eggs; and growing of corn, sunflower, and soybean seeds, as well as rape and wheat grains to third parties. MHP SE was founded in 1998 and is headquartered in Kiev, Ukraine.
Full MHPSY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.